In a 12-week single-arm study, 15 middle-aged Japanese women took 500 mg/day of NMN. Growth of anagen hairs and hair diameter increased, and subjective hair-quality and fatigue scores changed. The findings are preliminary because the trial had no placebo group.

A phase 1/2 trial gave oral NMN for two weeks to 25 adults with steroid-resistant or steroid-dependent immune thrombocytopenia. Five participants, or 20%, met the platelet-response criterion, suggesting an early metabolic approach involving the CD38–NAD+ axis.

A 2026 study gave oral NMN to D-galactose-induced aging-model mice for six weeks and reported improved spatial memory, increased antioxidant enzymes, reduced neuroinflammation, more butyrate-producing bacteria, and activation of Nrf2/HO-1. The findings are preclinical.

CD38 is an enzyme that increases with aging and degrades NAD+ and NMN. This article reviews three CD38-mediated pathways, the cycle involving cellular senescence and inflammation, and preclinical studies of CD38 inhibition by apigenin and quercetin.

“We retrieved oocytes, but none were of good quality.” “My AMH level is low.” These concerns point to a problem...

At NOMON & Co., we review the latest research on aging every day, guided by our vision of building a...